
Lilly’s Q1 2025 revenue jumps 45%, but CVS shift boosts Novo’s Wegovy
Eli Lilly has reported $12.73bn in Q1 2025 revenue, a 45% increase from the prior year, driven largely by demand for its diabetes and obesity drugs, Mounjaro (tirzepatide) and Zepbound (tirzepatide), respectively. But the announcement was quickly …